Physician

Andrew E Werchniak, MD

According to 2025 Medicare claims, Andrew Werchniak, MD (NPI: 1023075710) practices dermatology in the Rockingham County-Strafford County, NH market, with the plurality of this provider's patient population coming from Strafford, NH. This provider's primary affiliated billing organization is FOREFRONT DERMATOLOGY - NEW HAMPSHIRE, PLLC (NPI: 1295422707; TIN: 92-1854812) and primary practice location at 03820-3434.

Werchniak's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,427 traditional Medicare patients, billed 8,074 HCPCS/CPT codes, and received $280,915 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 965 prescription claims across 400 beneficiaries totaling $397,275 in drug costs, led by Otezla (Apremilast). No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $57,455 to $397,275. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$148K$296K2015 Medicare payment: $202,843 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $269,364 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $261,429 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $266,882 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $288,211 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $265,528 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $295,935 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $293,296 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $291,646 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $280,915 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20158123,846$202,843
20161,0485,750$269,364
20171,1906,176$261,429
20181,3026,985$266,882
20191,3556,865$288,211
20201,2456,556$265,528
20211,2247,519$295,935
20221,2997,899$293,296
20231,3368,228$291,646
20241,4278,074$280,915

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$311K$623K2015 Drug cost: $57,455 (USD; Tot_Drug_Cst)2016 Drug cost: $68,211 (USD; Tot_Drug_Cst)2017 Drug cost: $85,057 (USD; Tot_Drug_Cst)2018 Drug cost: $105,048 (USD; Tot_Drug_Cst)2019 Drug cost: $320,837 (USD; Tot_Drug_Cst)2020 Drug cost: $303,449 (USD; Tot_Drug_Cst)2021 Drug cost: $338,206 (USD; Tot_Drug_Cst)2022 Drug cost: $473,638 (USD; Tot_Drug_Cst)2023 Drug cost: $622,523 (USD; Tot_Drug_Cst)2024 Drug cost: $397,275 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015193392$57,455
2016279646$68,211
2017287615$85,057
2018316637$105,048
2019319752$320,837
2020341855$303,449
2021371898$338,206
2022339862$473,638
2023347898$622,523
2024400965$397,275

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more333460$89
17110Destruction of skin growth, 1-14 growths254289$78
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more1,0931,513$58
17000Destruction of precancer skin growth, 1 growth9601,367$42
17003Destruction of precancer skin growth, 2-14 growths7253,769$5

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
OtezlaApremilast23750$115,565
Dupixent PenDupilumab23644$92,720
Clobetasol PropionateClobetasol Propionate1123,678$6,740
AcitretinAcitretin18720$6,565
MetronidazoleMetronidazole1093,559$6,094

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

FAQ

What Medicare data is available for Andrew E. Werchniak, MD?

Tedicare shows public-source Medicare data for Andrew E. Werchniak, MD (NPI 1023075710), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Andrew E. Werchniak, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Andrew E. Werchniak, MD?

Andrew E. Werchniak, MD is linked to FOREFRONT DERMATOLOGY - NEW HAMPSHIRE, PLLC (billing NPI 1295422707) in the available physician profile data.

Does Andrew E. Werchniak, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.